SUN PHARMA Q2 FY27 CONCALL: MAINTAINS HIGH SINGLE-DIGIT FY27 REVENUE GROWTH GUIDANCE; ORGANON ACQUISITION TARGETED FOR Q4 FY27, R&D SPENDING TO ACCELERATE IN H2 & ILUMIA PSORIATIC ARTHRITIS LAUNCH PLANNED FOR NOVEMBER 2026